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ABSTRACT
REV1 is central to the DNA damage response of
eukaryotes through an as yet poorly understood
role in translesion synthesis. REV1 is a member of
the Y-type DNA polymerase family and is capable
of in vitro deoxycytidyl transferase activity opposite
a range of damaged bases. However, non-catalytic
roles for REV1 have been suggested by the
Saccharomyces cerevisiae rev1-1 mutant, which car-
ries a point mutation in the N-terminal BRCT domain,
and the recently demonstrated ability of the mamma-
lian protein to interact with each of the other transle-
sion polymerases via its extreme C-terminus. Here,
we show that a region adjacent to this polymerase
interacting domain mediates an interaction with
PCNA. These C-terminal domains of REV1 are neces-
sary,althoughnotsufficient,foreffectivetoleranceof
DNA damage in the avian cell line DT40, while the
BRCTdomain andtransferaseactivityarenotdirectly
required. Togetherthese data provide strong support
for REV1 playing an important non-catalytic role in
coordinating translesion synthesis. Further, unlike
in budding yeast, rad18 is not epistatic to rev1 for
DNA damage tolerance suggesting that REV1 and
RAD18 play largely independent roles in the control
of vertebrate translesion synthesis.
INTRODUCTION
The ability to bypass DNA damage encountered during rep-
lication is critical to the survival of a cell. Failure to do so
results in incomplete replication and cell death or the passage
of an aberrant genome to the cell’s progeny. Replication of
a damaged template is facilitated by two pathways, homo-
logous recombination and translesion synthesis. The former
is generally accurate and makes use of an alternative
undamaged template to allow the replicative polymerases to
bypass the lesion. The latter employs direct bypass of a lesion
by one or more of a number of specialized translesion poly-
merases (1). Because DNA lesions are often non- or mis-
instructional, and because these enzymes generally have a
higher misincorporation rate than the replicative polymerases,
this strategy will frequently result in mutation. Despite the
obvious risks of mutation in a multicellular organism, it has
recently become clear that not only do vertebrate genomes
encode translesion polymerases, but that higher eukaryotes
rely heavily on these enzymes for their ability to deal with
DNA damage (2).
Saccharomyces cerevisiae has two major translesion poly-
merases: RAD30 (DNA polymerase h) and DNA polymerase
z (comprising a catalytic subunit, REV3, and REV7). In addi-
tion, REV1, a member of the Y family of DNA polymerases,
plays an important, but ill-deﬁned, role in translesion syn-
thesis. REV1 was ﬁrst identiﬁed in a screen for genes required
for UV-induced mutagenesis (3). It possesses deoxycytidyl
transferase in vitro (4) and, there is good evidence from
diverse experiments in yeast that this activity contributes to
abasic site bypass in vivo (5–8), although one report has
claimed that the transferase activity is dispensable for muta-
genesis (9). A second, not directly catalytic role for REV1 in
DNA damage bypass has been inferred from an analysis of
the rev1-1 mutant. This mutant carries a point mutation in
the N-terminal BRCT domain of the protein (10) and, while
it retains much of its catalytic activity, it is deﬁcient in
damaged-induced mutagenesis (6). BRCT domains are found
in a number of proteins involved in DNA repair (11) and have
been implicated in mediating interactions with phosphopro-
teins (12,13). REV1 homologues are also found in higher
eukaryotes where they too play a key role in mutagenesis
and the DNA damage response (14–16) and, biochemically,
human REV1 has many of the same properties as its yeast
counterpart (17,18).
Clearly, the unrestrained activity of the translesion poly-
merases would be hazardous and there has been increasing
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sites of DNA damage. Recently, post-translational modiﬁca-
tions of POL30, the S.cerevisiae homologue of the sliding
clamp PCNA (proliferating cell nuclear antigen), have been
shown to play a major role (19–21). In response to DNA
damage, POL30 is monoubiquitinated at Lys-164 by the
RAD6/RAD18 heterodimer. In S.cerevisiae RAD6/RAD18
are epistatic to both REV1/POLz and POLh leading to the
suggestionthatthis monoubiquitinatedformofPCNA controls
the use of these enzymes. RAD18 has also been shown to
mediate the DNA damage-induced monoubiquitination of
PCNA in human cells and this modiﬁcation can recruit
DNA polymerase h (22,23).
However, there are a larger number of specialized transle-
sion polymerases in vertebrates than in yeast and so the regu-
lation of translesion synthesis is likely to be more complex.
It seems unlikely that RAD18 plays the same dominant
controlling role as it does in yeast: to date at least one
translesion polymerase, POLk, appears not to be under the
control of RAD18 (24). Recently, the observation that
mouse and human REV1 are able to interact with each of
the other translesion polymerases has also hinted at potential
differences in the control of vertebrate translesion synthesis
(25–28) since the region of REV1 responsible, the extreme
C-terminus, reportedly bears no homology to the yeast
protein (25). Although this observation has led to the sugges-
tion that vertebrate REV1 may also play a critical role
in choreography of translesion synthesis (26), albeit by
a perhaps different mechanism to yeast REV1, the func-
tional signiﬁcance of the three main domains of vertebrate
REV1 (N-terminal BRCT domain, transferase domain
and C-terminus) in DNA damage tolerance has not been
determined.
Here, we present evidence that the C-terminus of REV1
plays an essential role in the control of translesion synthesis,
we suggest through coordinating the interaction of the special-
ized translesion polymerases with PCNA. Further, we ﬁnd
that rad18 is not epistatic to rev1 in DT40 suggesting that
these genes play substantially, but perhaps not completely,
independent roles in the control of this complex process in
vertebrates.
MATERIALS AND METHODS
Mammalian-two-hybrid assays
pM and pVP16 plasmids (both from Clontech) were used to
create fusion proteins with the GAL4 DNA binding domain
and GAL4 activation domain (linked to the HSV transactiv-
ator, VP16) respectively. Pairs of potential interactors were
transfected into 2.5 · 10
6 293T cells together with an internal
control plasmid[pRL-CMV (Promega), encoding Renillaluci-
ferase]andaGAL4promoter-driven Fireﬂyluciferasereporter
plasmid. The cells were transfected using SuperFect (Qiagen)
following manufacturer’s procedures and harvested after 24 h.
Luciferase activity was determined using an Orion Lumino-
meter (Berthold Technologies). The Renilla luciferase readout
was used as internal control to normalize all transfections
within an experiment and interactions were calculated as
fold induction in Fireﬂy luciferase expression compared to
negative controls.
DNA constructions and site-directed mutagenesis
The chicken b-actin expression construct, pXPSN was created
by modifyingthe multiple cloning siteof the pExpressplasmid
(29) to give the following sites: HindIII–SalI–NheI–NotI. The
human REV1 open reading frame, and mutants thereof, were
cloned as SalI–NotI fragments into pXPSN cut HindIII–NotI
in a three-way ligationwitheYFP (Clontech) as a HindIII–SalI
fragment. This creates an N-terminal YFP fusion (eYFP is
referred to in this paper as simply YFP). The b-actin
promoter-YFP-REV1 cassettes were subsequently cloned into
pLoxBsr (29). rev1(1–826) was generated by PCR using
REV1FS (50-GCGTCGACCATGAGGCGAGGTGGATG-
GAGGAAGCGAGC) with R1827RN (50-TTTTCCTTTTGC-
GGCCGCTTAAGTTGGAACGAACTGATTCACG). rev1
(333–1251) and rev1(923–1251) were generated using
REV1RN (50-TTTTCCTTTTGCGGCCGCTTATGTAACT-
TTTAATGTGCTTCC) with R1333F (50-GCGTCGACCAT-
GGCAGCACCTTCAGTGCCATCC) and R1923F (50-GC-
GTCGACCATGTCGAGACTTAACCTGAGTATAGAGG-
TCCCG), respectively. Site-directed mutants were generated
using Quik-Change (Stratagene) following manufacturer’s
protocol using R1mutB (50-GATGTTGCATGGACGTCAA-
TACCATG) for the G76R BRCT mutant and R1mutC (50-
GAAGCTGTCAGTTGTGCTGCAGCGCTGGTAGACATT)
for the D570A/E571A catalytic mutant. Mutations were con-
ﬁrmed by DNA sequencing.
DT40 culture and transfection
DT40 and mutants were cultured as described previously (15).
pLoxBsr-YFP-hREV1 constructs were transfected by electro-
poration at 250 V and 950 mF into rev1 DT40. Transfected
clones were selected using 20 mg/ml Blasticidin (Invitrogen).
Surviving clones were analysed by cytometry using a
FACSCalibur ﬂow cytometer to detect YFP expression. For
generating the rad18 and rad18/rev1 mutants, a chicken rad18
targeting construct (30) was modiﬁed to contain selectable
markersforblasticidin andhistidinol.Transfection wascarried
out at 550 V, 25 mF with selection at 24 h. Clones were
screened for targeted integration by Southern blotting.
Mutagen sensitivity assays
Cellswereexposedto254nmUVlightdeliveredbyabenchtop
lamp (UVP Inc.) whose output was equilibrated for 10 min and
measured using a UV radiometer (UVP Inc.). They were then
plated on DMEM containing 1% 4000 cP methylcellulose as
previouslydescribed(15).Forcisplatinandhydrogenperoxide
sensitivitymeasurements,cellswereexposedtofreshlydiluted
cisplatin (Sigma) or H2O2 (BDH) for 1 h and then washed
before being plated out. Experiments were repeated two to
four times. For clarity only the positive error (SD) is shown.
Analysis of sister chromatid exchange
This was performed as described previously (15).
Confocal microscopy
Cells were allowed to adhere to poly-L-lysine coated slides and
treated with Fix & Perm (Caltag) following manufacturer’s
instructions. Cells were mounted in VectaShield containing
DAPI (Vector Laboratories Inc.) and were viewed using
Nikon Eclipse TE300/Biorad Radiance Confocal Microscope.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1281Images were collected with LaserSharp2000 (Biorad) and pro-
cessed using Adobe PhotoshopCS.
RESULTS
A region adjacent to the C-terminal translesion
polymerase-interacting domain of hREV1 mediates
an interaction with PCNA
During a yeast two-hybrid screen for proteins that interacted
with human DNA polymerase h, we identiﬁed a C-terminal
fragment of REV1 (C. Chu-Wai-Chow, Anna-Laura Ross and
Julian E. Sale, unpublished observations). We conﬁrmed this
interaction in a mammalian two-hybrid system with full-
length REV1 and showed dependence on the extreme
C-terminus of REV1 (Figure 1A and B), as has been recently
reported (26–28). A further survey of interactions between the
human homologues of the yeast RAD6 epistasis group, again
using a mammalian-two-hybrid system, revealed, among
several known interactions, an interaction of human REV1
with PCNA (Figure 1A).
Although this interaction is only seen in one orientation
(when PCNA is in pM, the GAL4 binding domain plasmid),
it is clearly also mediated by the C-terminus of REV1
(Figure 1B). A ﬁner dissection of the C-terminus suggests
that the region responsible for this interaction lies adjacent
to the polymerase interacting domain, likely between amino
acids 923 and 1047 (Figure 1C). Although this region contains
at least one sequence(QVDPEVFat 1015–1021)that remotely
resembles a PCNA binding motif [QXXhXXa, where ‘h’ is a
hydrophobic residue and ‘a’ is aromatic (31)], we could not
detect an interaction between PCNA and REV1 in a yeast
two-hybrid assay (data not shown) suggesting that it may
be indirect.
Conservation of the C-terminus of REV1
While human and mouse REV1 have been shown to interact
with each of the other TLS polymerases, to date no physical
interaction between yeast REV1 and POLz or RAD30 has
been reported. Indeed, it has been suggested that a similar
interaction between the C-terminus of yeast REV1 and the
other yeast TLS polymerases is unlikely because of the lack
of sequence homology between this region of the yeast and
human proteins (25). We re-examined the homology in the
C-terminus of REV1 from a range of eukaryotes. Using
PSI-BLAST with the C-terminal 100 amino acids of human
REV1, we were able to identify REV1 homologues down to
S.cerevisiae, although notably plant sequences were absent
(e.g. Arabidopsis and Oryza) (Figure 1D). All of the sequences
identiﬁed using the human C-terminus, including that from
Gallus gallus, also contain an N-terminal BRCT domain and
central IMS/DinP nucleotidyl transferase/polymerase domain.
An exception was a sequence from Apis mellifera (honeybee),
which contained a transferase domain but no BRCT domain.
As expected, conservation of the C-terminal region is high
among vertebrates, 78% between pufferﬁsh and human,
and 96% between rat and human. Secondary structure predic-
tion using 3D-PSSM (32) suggests this region in the human
protein encodes a pair of coiled-coil domains with similarity
to a number of domains known to mediate protein–protein
interactions, including the bromodomain and spectrin
repeat. Unexpectedly however, there is also signiﬁcant
conservation of this region between human and Drosophila
melanogaster (19%), Schizosaccharomyces pombe (24%)
and Saccharomyces cerevisiae (17%). Despite only 19%
identity, the C-terminus of Drosophila REV1 has been used
to purify the REV3 subunit of POLz (33) suggesting that the
function of this region is likely to be conserved at least
between humans and ﬂies, a point we consider further below.
Human REV1 complements the UV and cisplatin
sensitivity of the DT40 rev1 mutant
Vertebrate REV1 therefore appears to have three key regions:
the N-terminal BRCT domain, central transferase domain and
the TLS polymerase interaction region at the C-terminus. To
clarify the functional importance of these three regions in vivo,
we adopted a complementation strategy in a rev1 mutant of the
chicken cell line DT40 (15). As no good antibodies against
REV1 have been reported to date, we constructed a fusion
protein in which enhanced yellow ﬂuorescent protein (eYFP,
Clontech Laboratories) was fused to the N-terminus of human
REV1. Attempts to induce stable expression of this construct
using strong promoters, such as the cytomegalovirus IE pro-
moter, were unsuccessful despite being able to demonstrate
transient expression of the fusion protein from this construct
in COS cells (data not shown). However, using a chicken
b-actin promoter, we were able to reliably obtain stable
YFP positive clones. Interestingly, the steady-state level of
expression of the fusion protein in these clones was not
high, producing between a half and one log shift in ﬂuore-
scence (Figure 2A). Nevertheless, this level of expression was
sufﬁcient to restore the growth characteristics and hypersens-
itivityofrev1cellstoUVlightandcisplatintowild-typelevels
(Figures 2B and 4D and data not shown), while YFP negative
transfectants retained the rev1 phenotype (Figure 2). Thus,
human REV1 is able to complement the chicken rev1 mutant.
The N-terminus is required for efficient nuclear
localization of hREV1
Using the same technique, we created a panel of rev1
DT40 expressing mutated/truncated human REV1 constructs.
We assessed localization of the fusion proteins by examining
YFP ﬂuorescence using laser scanning confocal microscopy.
The full-length REV1 and all mutants, with the exception of
rev1(333–1251) and rev1(923–1251), were strongly localized
to the nucleus (Figure 3). rev1(333–1251) is expressed both in
the nucleus and cytoplasm despite the deleted N-terminal
region containing no obvious nuclear localization signal. In
none of the clones examined did we detect clear focus forma-
tion in either untreated or UV irradiated cells. We discuss both
these observations below.
The N-terminus, including the BRCT domain, of hREV1
is dispensable for efficient DNA damage tolerance
The rev1-1 mutant in yeast (3) carries a point mutation in
the N-terminal BRCT domain resulting in a G193R amino
acid substitution (10). This renders the cells sensitive to
UV irradiation (34) and yet the mutant protein retains sub-
stantial deoxycytidyl transferase activity (6). This observation
1282 Nucleic Acids Research, 2005, Vol. 33, No. 4Figure 1. (A) Mammalian two-hybrid interactions of REV1 and PCNA. Luciferase activity is expressed as a multiple of the negative control. The bait, in pM is
indicated at the top of each graph and the prey, in pVP16, under each column. (B) The C-terminus of REV1 is responsible for both the interaction with POLh and
PCNA.Representativemammalian-two-hybridluciferaseassaysfortheinteractionofPOLhandPCNAwithfull-length(FL)REV1andtruncationmutantsthereof.
(C) Summary of mammalian two-hybrid readouts between REV1 mutants (in pM) and POLh or PCNA (in pVP16). The grey box indicates the region shared by all
REV1 truncations that give a positive interaction with PCNA. (D) ClustalW (http://www.ebi.ac.uk/clustalw/) alignments of C-terminus of REV1 homologues
identifiedduringaPSI-BLAST(http://www.ncbi.nlm.nih.gov/BLAST/)searchwiththeC-terminal100aminoacidsofhumanREV1.Alltheseproteinsadditionally
possess N-terminal BRCT domains and central transferase domains. The shades of grey indicate the degree of conservation derived from the BLOSUM62 score
calculated in Jalview (http://www.jalview.org/) using the ClustalW alignment. The amino acid positons are indicated at the beginning of each line. The number of
the final amino acid of each sequence is given at the end of the second line. Species abbreviations: Hs, Homo sapiens; Rn, Rattus norvegicus; Mm, Mus musculus;
Gg, Gallus gallus (chicken); Xl, Xenopus laevis; Tn, Tetraodon nigroviridans (pufferfish); Dm, Drosophila melanogaster; Gz, Gibberella zeae; Cg, Candida
glabrata; Cn, Cryptococcus neoformans; Eg, Eremothecium gossypii; Mg, Magnaporthe grisea; Um, Ustilago maydis; Sp, Schizosaccharomyces pombe;
Sc, Saccharomyces cerevisiae.
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tion of REV1 from a second role in translesion synthesis.
The corresponding residue in human REV1 is G76 (35) and
we therefore constructed a YFP-hREV1 fusion carrying a
G76R substitution. Surprisingly, the expression of this con-
struct was able to complement the UV and cisplatin sensitivity
of rev1 DT40 (Figure 4A).
We therefore asked whether the whole N-terminus, encom-
passing the BRCT domain, was dispensable (Figure 4B).
A construct lacking the ﬁrst 332 amino acids was also able
to restore UV and cisplatin sensitivity of rev1 DT40 to wild-
type levels. However, expression of this construct is seen in
both the nucleus and cytoplasm. Such delocalization was also
noted by Tissier et al. (27) during transient expression of a
more extensive N-terminal deletion of the ﬁrst 729 amino
acids. While in this latter system expression was predomin-
antly nuclear, in our stably transfected lines rev1(333–1251)
expression is predominantly cytoplasmic. Further, unlike full-
length REV1, it was possible to obtain clones of rev1(333–
1251) with much higher levels of expression (data not shown).
This may reﬂect the poor nuclear retention of the mutant
protein, allowing higher levels of expression without toxicity.
The catalytic activity of hREV1 does not play a major
role in tolerance of damage induced by UV light,
cisplatin or hydrogen peroxide
The transferase activity of REV1 depends on key motifs in
polymerase domains III and IV. We mutated the critical DE
motif in domain IV by changing D570 and E571 to alanine.
This mutation has previously been shown to abolish the trans-
ferase activity of the protein (36). Expression of catalytically
inactive REV1 in rev1 DT40 resulted in complementation of
thecellularhypersensitivitytoUVlight(Figure4C).However,
since neither T–T dimers nor 6–4 photoproducts are substrates
for dCMP transfer by REV1 in vitro, this result does not
exclude a role for the dCMP transferase activity in the bypass
of other lesions. Hydrogen peroxide causes a wide range of
oxidative base lesions including abasic sites, which are known
substrates for REV1 (4,17). We therefore additionally
examined the response of the catalytic mutant to hydrogen
peroxide. The D10 values for hydrogen peroxide (dose at
which 10% of cells survive) of wild-type cells was
19.4 – 3.0 mM, while for rev1 cells it was 7.2 – 3.7 mM.
The value for the rev1(D570A/E571A) mutant was 25.6 –
6.9 mM. Thus, rev1(D570A/E571A) is also able to comple-
ment the hypersensitivity of rev1 cells to hydrogen peroxide.
This suggests that dC transfer is not the principal function of
REV1 for tolerance of DNA damage created by these muta-
gens.
It has emerged recently that the efﬁcient repair of inter-
strand cross-links in vertebrates requires the translesion poly-
merases POLz (37) and POLh (38) as well as REV1 (15). The
precise role they play is unclear, but one attractive model is
that they bypass the adducted mononucleotide remaining fol-
lowing the incision and degradation of one strand of the cross-
linked DNA (39). Similar to the ﬁndings for UV and hydrogen
peroxide, the catalytic activity of REV1 is dispensable for its
role in processing cisplatin-induced damage (Figure 4C).
The C-terminus of REV1 is necessary but not sufficient
for effective DNA damage tolerance
Further conﬁrmation of the dispensability of the BRCT
domain and transferase activity of REV1 comes from com-
plementation with rev1(1–827). This mutant contains both
BRCT and transferase domains and yet fails to restore the
hypersensitivity of rev1 DT40 to UV and cisplatin (Figure
4D), despite being correctly localized in the nucleus (Figure
3B). This result also demonstrates the critical importance of
the C-terminus of the protein. We noted that rev1 cells
expressing rev1(1–827) appeared slightly more sensitive to
UV light than rev1 cells suggesting a possible dominant neg-
ative role for this construct. However, expression of rev1(1–
827)inwild-type cells did notconferany signiﬁcantadditional
sensitivity to UV (data not shown). We next asked whether the
C-terminus alone, rev1(923–1251), was sufﬁcient to restore
the DNA damage sensitivity of the rev1 mutant. It is not
(Figure 4E). In addition, we tested rev1(1150–1251) and
found that it also failed to complement the rev1 defect
(data not shown). However, expression of the rev1(923–
1251) mutant results in a rather granular YFP signal through-
out both the nucleus and cytoplasm suggesting that the protein
may be aggregating.
REV1 acts largely independently of RAD18
Our data suggest that REV1 is playing a structural role in
translesion synthesis probably through coordination of the
other translesion polymerases at a lesion, including those
not found in yeast, POLk and POLi. In yeast, RAD18 plays
a key role in the control of the TLS polymerases POLz and
RAD30 (POLh) and is epistatic to both (19,20,40). In verteb-
rates, RAD18 has been shown to be involved in the regulation
of POLh recruitment, but does not appear to be epistatic to
POLk (22–24). These data, the importance of REV1 in ver-
tebrate TLS and the apparent universality of its interaction
with the TLS polymerases, led us to examine the genetic
relationship betweenRAD18 and REV1 inDT40 by construct-
ing a rev1/rad18 double mutant.
The rev1 mutant grows more slowly than wild-type cells
(15) whereas the rad18 mutant does not exhibit such defect
Figure 2. Complementation of rev1 DT40 with human REV1. (A) Typical
expression of eYFP-tagged human REV1 in rev1 DT40 compared with a non-
expressing control from the same transfection. (B) UV sensitivity of the two
clonesshowninFigure2Acomparedwithwild-typeDT40andtherev1mutant.
Key: squares, WT; diamonds, rev1; triangles, rev1:YFPhREV1 YFP negative
clone; circles, rev1:YFPhREV1 YFP positive clone.
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growth to the rev1 single mutant (data not shown). A key
feature of rad18 mutants of both DT40 and mouse embryonic
stem cells is the elevated levels of spontaneous sister
chromatid exchange, which has been interpreted as channel-
ling of lesions from post-replication repair into homologous
recombination (30,41). rev1 mutants do not show this eleva-
tion and, making the assumption that rad18 would be epistatic
to rev1 in DT40, we previously suggested that this might
mean that REV1 is beyond a point of commitment in lesion
bypass that cannot be ‘rescued’ by homologous recombination
(15). The observation (Figure 5A) that the rev1/rad18
double mutant displays elevated SCE similar to the rad18
single mutant is consistent with this. However, testing for
sensitivity to UV light and cisplatin shows the rev1/rad18
double mutant to be considerably more sensitive than
either single mutant (Figure 5B). Further, and in contrast to
yeast, we consistently observed the rev1 mutant to be more
sensitive than the rad18 mutant to all agents tested. Taken
together, these data are most readily explained by RAD18 and
REV1 playing largely non-overlapping roles in DNA damage
tolerance.
Figure 3. ExpressionandlocalizationofREV1andmutantsinDT40cells.(A)ExpressionlevelsbyflowcytometryofeYFPfluorescenceinrev1DT40transfected
with full-length and mutant YFP-hREV1 fusions. FL, Full-length hREV1. (B) Localization of REV1 and mutants by confocal microscopy. REV1 in green,
DNA stained by DAPI in blue. Colocalization results in cyan.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1285Figure 5. (A) Spontaneous and DNA damage-induced sister chromatid
exchange (SCE) in rev1/rad18 DT40. These histograms represent the per-
centage of metaphases (y-axis) containing a given number of SCE (x-axis).
Untreatedindarkgrey,cellstreatedwithNQOinlightgrey.MeanSCE:WT1.4
(n=254)[+NQO4.7(n=140)];rad188.5(n=125)[+NQO12.3(n=75)];rev1
2.0(n=119)[+NQO3.4(n=63)];rev1/rad187.1(n=72)[+NQO11.0(n=50)].
(B)EpistasisanalysisforsurvivalfollowingDNAdamageinrev1/rad18DT40
following treatment with 254 nm UV and cisplatin. Key: squares, WT; dia-
monds, rev1; circles, rad18; triangles, rev1/rad18.
Figure 4. A 254 nm UV and cisplatin damage sensitivity of rev1 mutants.
(A) BRCT mutant, rev1(G76R)( B) N-terminal BRCT truncation mutant,
rev1(333–1251). (C) Catalytic mutant rev1(D570A/E571A). (D) C-terminal
truncation mutant, rev1(1–827). (E) C-terminus only mutant, rev1(923–
1251).Key:squares,WT;diamonds,rev1;circles,rev1expressingtheindicated
YFP fusion; triangles, rev1 expressing full-length YFP-hREV1.
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Expression and localization of Rev1
We believe that REV1 expression is likely to be tightly regu-
lated at low levels in cells. Although human REV1 is able to
complement the rev1 defect in a chicken cell line, it does
so only at modest expression levels. Attempts to obtain
stably overexpressing lines using a strong (CMV-IE) promoter
were unsuccessful whereas use of the chicken b-actin pro-
moter appears to allow selection of clones with levels of
expression closer to expected physiological levels. Like
REV3, the human REV1 locus contains an upstream ATG
which will give rise to an out-of-frame transcript predicting
that expression levels will be low (42) and to date there has
been no successful detection of endogenous REV1 using
immunoﬂuorescence in vertebrate cells. In S.cerevisiae,i ti s
estimated that there are only about 500 molecules of REV1
per cell (43).
The only mutant that could be readily driven to higher
constitutive levels of expression was rev1(333–1251),
which lacks the N-terminus including the BRCT domain.
Expression of this mutant in our stably transfected cells is
seen predominantly in the cytoplasm. We do not believe
this result is inconsistent with that of Tissier et al. (27),
although a direct comparison between the experimental sys-
tems employed is difﬁcult as we believe that stable expression
of REV1 selects against high nuclear levels of the protein. The
N-terminus of REV1 does not contain any likely nuclear loc-
alization signal, so we think it is probable that efﬁcient nuclear
retention of REV1 requires the BRCT domain. However,
rev1(333–1251) is still able to complement the DNA damage
hypersensitivity of rev1 DT40. This suggests that the N-
terminus is not essential for the direct role played by REV1
in translesion synthesis. In the context of the endogenous
REV1 promoter, such a defect in the BRCT domain may mani-
fest itself as a null or hypomorphic phenotype, not because this
domain plays a direct role in the coordination of TLS, but
because of insufﬁcient nuclear levels of the C-terminus,
which our data show to be essential. Indeed, murine ES
cells carrying a REV1 BRCT domain deletion show a pheno-
typesimilartorev1DT40 (16).Thattheequivalentmutationto
yeast rev1-1 in the human protein does not disrupt localization
or function may be due to differences in the ﬁne structure of
the domainbetween yeast andvertebrates ora manifestationof
a different mode of action of yeast REV1: it would be inter-
esting to determine whether the rev1-1 mutant in yeast is
correctly localized.
Two recent reports (27,28) and our own unpublished
observations have shown that a proportion of mammalian
cells transiently overexpressing REV1 show spontaneous
focus formation. Transient transfection, in COS or HeLa
cells, of CMV-IE promoter-driven YFP-REV1 results in a
spectrum of expression ranging from faint and diffuse,
through foci of varying sizes to clearly unphysiological
aggregates. In our stably transfected rev1 DT40 cells, we
do not observe such foci either spontaneously or following
DNA damage: YFP ﬂuorescence in the nucleus remains
diffuse, and relatively faint. We do not believe that this
reﬂects failure of recruitment of YFP-tagged REV1 to sites
of stalled replication, since we see complementation of the
DNA damage hypersensitivity of rev1 DT40. Although we
believe that the REV1 foci seen in transient overexpression
experiments are probably tag sites of recruitment, we think it
more likely that the actual physiological function of REV1 at
sites of stalled replication does not require more than a few
molecules.
The interactions of REV1 in higher and
lower eukaryotes
Recent data (25–28), and that presented here, have shown that
the extreme C-terminus of human and mouse REV1 is able to
bindeach ofthe othertranslesion polymerases.From the align-
ments presented in Figure 1 and the fact that the human gene is
able to complement a chicken mutant, it seems likely that this
will be a universal feature in vertebrates. Contrary to previous
assertions (25), we do not agree that the C-terminus of REV1
of S.cerevisiae exhibits no signiﬁcant homology with the ver-
tebrate protein. The alignments of the extreme C-terminus of
the human and yeast proteins reveal some strikingly conserved
features despite a relatively low percentage overall identity.
Highly relevant in this regard is the fact that a similar level
of conservation is seen between human and Drosophila as is
seen between human and S.cerevisiae REV1. Recently, bio-
chemical experiments have shown that it is possible to purify
Drosophila REV3 by afﬁnity chromatography with the
C-terminus of Drosophila REV1 (33). While it is unclear
whether this is actually achieved via an intermediate REV7
interaction (25), it would seem likely that the human and ﬂy
REV1 are working in the same way. These observations beg a
careful re-examination of the interactions and role of REV1 in
yeast. Indeed, the observations of Larimer et al., some ﬁfteen
years ago, suggest that deletion of the C-terminal 128 amino
acids of REV1 in S.cerevisiae also results in the null pheno-
type: UV-induced Lys
+ revertants from lys1-1 in this mutant
were comparable to the level seen in the rev1-1 mutant, while
a strain producing a REV1 transcript truncated just 30 of the
stop codon was Rev
+ (10). However, there is no apparent
conservation of this domain between vertebrates and plants,
exempliﬁed by Arabidopsis and Oryza, suggesting that
the REV1-TLS polymerase interaction is not likely to be
conserved in all eukaryotes.
A novel interaction identiﬁed in the current work is that
between the C-terminus of REV1 and PCNA. Our data further
suggests that the interactions of the TLS polymerases and
PCNA involve adjacent regions of the C-terminus of REV1.
Althoughthe interaction ofREV1 with PCNA may be indirect,
transiently overexpresssed REV1 has been shown to colo-
calize with POLh and PCNA in ‘replication factories’ (27),
with the localization of REV1 appearing to be independent of
POLh. Thus, REV1 may be required to coordinate or stabilize
the interaction of the incoming TLS polymerase with the
PCNA clamp.
The roles of REV1 and RAD18 in the control of
vertebrate translesion synthesis
REV1 is a member of the Y-type polymerase family and the
human protein exhibits in vitro dCMP transferase activity over
a wide range of lesions (17,18,44). However, although it is
unable to bypass both UV-induced T–T cyclobutane dimers
and 6–4 photoproducts, it is clearly required for normal tol-
erance of these lesions in DT40, suggesting that its role is
Nucleic Acids Research, 2005, Vol. 33, No. 4 1287not a function of its catalytic activity. The data we present here
unambiguously shows this to be the case, not only for UV-
induced damage, but also for oxidative base damage induced
by hydrogen peroxide and the complex damage introduced by
cisplatin. The principal function of the protein appears to
derive exclusively from the C-terminus further suggesting
that its major role in vertebrates is non-catalytic. We suggest
that REV1 is required for stabilization of the interaction
between the incoming TLS polymerase and PCNA at sites
of replication blockage. This stabilizing role may be enhanced
by the as yet unidentiﬁed interactions of the N-terminal BRCT
domain and possibly the DNA binding activity of the trans-
ferase domain. However, in the complementation system
presented in this paper, any loss of function of these domains
is overcome, possibly because there is still an element of
REV1 overexpression.
In S.cerevisiae RAD6/RAD18 are epistatic to the trans-
lesion DNA polymerases. Recent work has shown that the
RAD6/RAD18 heterodimer mediates the DNA damage-
induced monoubiquitination of PCNA (POL30 in yeast)
(19,21). In turn, this modiﬁcation is required to recruit tran-
slesion synthesis by POLz and RAD30. Human RAD18 has
also been shown to be responsible for the monoubiquitination
of PCNA and that monoubiquitinated PCNA speciﬁcally
recruits POLh to sites of replication arrest (22,23). However,
we show here that the function of REV1 in DNA damage
tolerance in DT40 is signiﬁcantly independent of RAD18.
A similar observation has also been made for DNA poly-
merase k (24). Together this suggests that the role RAD18
plays in the regulation of vertebrate translesion synthesis is not
as central as its yeast counterpart. Indeed, it is possible that in
vertebrates the RAD18-mediated monoubiquitination of
PCNA is only required for the recruitment of POLh. However,
while it is possible that in vertebrates there exist alternate
REV1-dependent and RAD18-dependent modes of translesion
synthesis, we favour the idea that both are required and that
in the absence of either, the coordination of the polymerases
becomes inefﬁcient resulting in decreased DNA damage tol-
erance. The precise mechanism by which REV1 and RAD18
interact in translesion synthesis will be a fertile ground for
further work.
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